Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.84 -2.56 (-4.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
34 35 Next >
News headline image
Alleged Industrial Espionage Makes an Interesting Story ↗
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. 
Via The Motley Fool
News headline image
Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit? ↗
There's more than one reason to sell a stock while buying another. 
Via The Motley Fool
News headline image
Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030 ↗
This company has several catalysts for growth coming up, with more on the way. 
Via The Motley Fool
News headline image
Is CRISPR Therapeutics Stock a Buy Now? ↗
CRISPR stock has climbed more than 40% so far this year. 
Via The Motley Fool
News headline image
3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever ↗
Here are three long-term biotech stock investments that have the opportunity to turn risk -tolerant investors into millionaires. 
Via InvestorPlace
News headline image
Where Will CRISPR Therapeutics Be in 10 Years? ↗
The biotech is part of a revolution in gene-editing therapies. 
Via The Motley Fool
News headline image
What 17 Analyst Ratings Have To Say About CRISPR Therapeutics ↗
 
Via Benzinga
News headline image
Can This Gene-Editing Stock Deliver 10X Returns? ↗
Buying shares of Intellia Therapeutics might be a smart move. 
Via The Motley Fool
News headline image
CRISPR Therapeutics: A Galaxy's Worth of Deep Value ↗
Wall Street is at max pessimism with this biotech, which might be a big mistake. 
Via The Motley Fool
News headline image
Here's the Secret Behind Cathie Wood's Latest Moneymaking Strategy ↗
Success could be in the DNA of the Ark Invest founder. 
Via The Motley Fool
News headline image
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators... 
Via Talk Markets
News headline image
3 Cathie Wood Investments That Could Deliver Superior Returns ↗
These three stocks fit Wood's profile for big-time growth. 
Via The Motley Fool
News headline image
2 Short-Squeeze Candidates That Could Go Parabolic ↗
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately. 
Via The Motley Fool
News headline image
This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics? ↗
All eyes are on CRISPR Therapeutics' gene editing technology. 
Via The Motley Fool
News headline image
5 Stocks to Buy With Explosive 500% Potential ↗
Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential. 
Via InvestorPlace
News headline image
2 Biotech Stocks That Could Help Make You a Fortune ↗
Biotech stocks with cutting-edge therapies have the potential to generate substantial returns over time. 
Via The Motley Fool
News headline image
3 No-Brainer Stocks to Buy in June ↗
These biopharma stocks could be big winners. 
Via The Motley Fool
News headline image
Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics' Exa-cel Application ↗
The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (NASDAQ: CRSP) exa-cel for sickle cell disease and transfusion-dependent  
Via Benzinga
News headline image
Vertex/CRISPR Partnered Cell Therapy Shows Encouraging In Sickle Cell Disease, Thalassemia Patients ↗
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) announced that pivotal trials for exagamglogene autotemcel (exa-cel) for transfusion-dependent... 
Via Benzinga
News headline image
Carvana (CVNA) Stock Continues to Move on Improved Outlook ↗
Carvana (CVNA) stock is still a hot topic among traders on Friday after the used-car retailer updated its outlook yesterday. 
Via InvestorPlace
News headline image
TGT Stock Alert: Have Target’s Sales Numbers Peaked? ↗
Target (TGT) stock is in hot water on Friday after Citi analyst Paul Lejuez warned investors to stay away from the retailer. 
Via InvestorPlace
News headline image
Why Is CRISPR Therapeutics (CRSP) Stock Moving Today? ↗
CRISPR Therapeutics (CRSP) stock is on the move Friday after the company revealed data from its CLIMB-111 and CLIMB-121 clinical trials. 
Via InvestorPlace
News headline image
Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months ↗
The agency said it will make an approval decision on Crispr's exa-cel in December. 
Via Investor's Business Daily
News headline image
Wall Street Loves These 3 Growth Stocks -- Should You? ↗
Analysts think all three of these stocks could soar. 
Via The Motley Fool
News headline image
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗
Today, CRISPR has reached an important turning point. 
Via The Motley Fool
News headline image
Cathie Wood Is Buying the SEC Lawsuit Dip in Coinbase (COIN) Stock ↗
Coinbase and the crypto industry at large is at war with regulators. But Cathie Wood is still buying shares of COIN stock. 
Via InvestorPlace
News headline image
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today? ↗
Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector. 
Via InvestorPlace
News headline image
3 Top Healthcare Stocks to Buy for June ↗
These stocks have what it takes to deliver long-term growth. 
Via The Motley Fool
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.